Watch the videos below to learn how others overcame challenges like securing funding, clearing scientific roadblocks, and navigating the competitive biotech landscape, then contact us to get started on your path to market.
Episode 1: RNAi and CRISPR/Cas9: Advanced Engineering for Modeling Human Disease for Drug Discovery | Prem Premsrirut
In this episode, Prem shares how she built a leading RNAi and CRISPR/Cas9 modeling technology through spinning out and securing funding from several types of investors.
Episode 2: An Integrated, Turnkey Venture Capital Model for Catalyzing Company Creation in the Life Sciences Industry | Jonathan Mandelbaum
In episode 2, Jonathan discusses the venture creation bottleneck idea and how it is due to the limited access and number of truly early stage venture capital investors. He shares the Accelerator model which enables early stage biotech to go from investment to full lab operation in two months’ time.
Episode 3: Case Study: Accelerating Time to Market Using an IDD Approach | Omar Aziz
In episode 3, Omar shares the main reasons why drug programs fail. He outlines a successful program- one in which quality, speed and cost are monitored closely and one that that tracks how the molecule/compound will translate from start to finish.
Episode 4: From NIH to a Biotech | Jolly Mazumdar
In episode 4, Jolly shares an intimate look at the ups and downs of building a company that develops novel RNA delivery platform technologies within oncology, infectious diseases and rare genetic disorders therapeutic areas.
Episode 5: How a start up became profitable without VC | Jacob Glanville
In episode 5, Jake shares how he was able to grow his company without outside funding sources and he continually turns his therapeutic innovations into reality.
Episode 6: The Bridge Model: Stimulating NYC Biotech Innovations from 3 Premier Institutions | William J. Polvino
Drug development is a race – time matters. In episode 6, Bill expands on this idea and shares how a collaboration between academia and private sources can accelerate time to market.
Episode 7: Using Computational Tools and AI to Develop New Drug Candidates | Edward Painter
In episode 7, Ed Painter brings his unique business perspective to drug discovery, attributing to the success of his organization, A2A Pharmaceuticals. A2A uses AI to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.
Episode 8: De-risking Therapeutics Projects from Academia to Industry: The NYU Office of Therapeutics Alliances Approach | Nadim Shohdy
Therapeutics Alliances is a unique and comprehensive drug accelerator that operates like a “virtual biotechnology company” to identify and de-risk select NYU projects and enable greater dealmaking with investors and biopharmaceutical companies. In episode 8, Nadim expands on this highly successful model for drug development.
Prem Premsrirut, Mirimus, Inc.
Episode 1: RNAi and CRISPR/Cas9: Advanced Engineering for Modeling Human Disease for Drug Discovery
Prem founded and has served as President and CEO of Mirimus, Inc. since 2010. Mirimus specializes in developing platform technology for genetic manipulation of animal models of human disease and therapeutic modeling for drug discovery research. Their work accelerates pipelines of bench to bedside discoveries using RNA interference and CRISPR/Cas gene editing technologies. Dr. Premsrirut was an MD/PhD Medical Scientist fellow at the SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory.
Jonathan Mandelbaum, PhD, Accelerator
Episode 2: An Integrated, Turnkey Venture Capital Model for Catalyzing Company Creation in the Life Sciences Industry
Jonathan joined Accelerator in 2015 to focus on investment opportunity sourcing, due diligence, new company formation, project management, and corporate business development. He obtained his PhD with Distinction in cellular, molecular and biophysical studies from Columbia University and received a BSc with Great Distinction in biology from McGill University.
Omar Aziz, PhD, Charles River
Episode 3: Case Study: Accelerating Time to Market Using an IDD Approach
Omar is the Director of Biology at Charles River's Early Discovery unit in Cambridge, UK which partners with companies to develop new compounds. He has a PhD from the University of Newcastle-upon-Tyne and completed his postdoctoral studies at the NIEHS, Research Triangle Park in North Carolina.
Jolly Mazumdar, PhD, MBA, Chimeron Bio
Episode 4: From NIH to a Biotech
Jolly is CEO of Chimeron Bio. Prior to Chimeron, she served in clinical development leadership roles at GlaxoSmithKline in the divisions of Immuno-oncology and Personalized Oncology. She obtained her PhD in cell biology from the University of Georgia and has an MBA from Columbia Business School.
Jacob Glanville, PhD, Distributed Bio
Episode 5: Computational Immunology: How Big Data in Immune Science Enabled the Startup Distributed Bio to Become Profitable Without Venture Capital
Jake, Founding Partner and CSO of Distributed Bio, is an entrepreneur and computational immuno-engineer. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing, repertoire decoding algorithms, single-cell TCR receptor & phenotype sequencing, and computationally guided antibody library engineering.
William J. Polvino, MD, Bridge Medicines
Episode 6: The Bridge Model: Stimulating NYC Biotech Innovations from 3 Premier Institutions
Bill is currently CEO of Bridge Medicines, a company established in 2016 to further the development of drugs nurtured by the Tri-Institutional Therapeutics Discovery Institute. The Tri-I TDI, as it’s known, is a nonprofit that brings together Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, The Rockefeller University and Takeda Pharmaceutical Company Ltd. to support investigations into promising therapeutics.
Edward Painter, A2A Pharmaceuticals
Episode 7: Using Computational Tools and AI to Develop New Drug Candidates
Former analyst at Goldman Sachs and Salomon Brothers, and former Senior VP at UBS, Oppenheimer & Co., Credit Suisse and Kidder Peabody, Edward Painter has more than 30 years of experience in finance. He has extensive experience working with biotech companies in financing and investment decisions.
Nadim Shohdy, PhD, Therapeutics Alliances
Episode 8: De-risking Therapeutics Projects from Academia to Industry: The NYU Office of Therapeutics Alliances Approach
Nadim is Assistant Dean, Therapeutics Alliances at the NYU School of Medicine, and Co-Founder and Director of its Office of Therapeutics Alliances (OTA). OTA is a drug discovery accelerator that advances NYU biomedical research to a far more validated stage to enable greater partnerships with biopharma, investors, and nonprofits to increase the odds of success for new NYU-discovered drugs helping future patients.